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Introduction
Malignant glioma is the most common brain tumor in adults 
and  has  a  very  poor  prognosis:  patients  diagnosed  with 
the most malignant form of the tumor live ~14 months after 
diagnosis.1,2 Although traditional treatments, such as surgical 
removal of the malignant tissue, chemotherapy, and radiation 
therapy often improve the outcome, additional therapies are 
still needed.3,4 Despite the significant development of thera-
pies for several other types of cancer, the median survival of 
malignant glioma patients has shown little improvement over 
the past few decades.5 Malignant glioma, as with most brain 
tumors, is a localized, rarely metastasizing tumor surrounded 
by nondividing cells, which makes it a well-defined target for 
gene therapy.6,7
Tumorigenesis is a complex process which involves sev-
eral molecular and cellular mechanisms. One of the central 
molecules  is  the  nonreceptor  protein  tyrosine  kinase  Src, 
which is a multifunctional signalling molecule located down-
stream of several different growth factor receptors.8,9 It has a 
major role in cellular processes such as migration, invasion 
and survival which are necessary for tumorigenesis.10 Src 
has been shown to play a role in several different cancers at 
varying stages of disease, including malignant glioma, which 
makes it an attractive target for therapy.11 However, most of 
the studies conducted so far have addressed the role of Src 
in tumorigenesis either in Src-deficient mice or with pharma-
cological inhibitors of Src.12–14
Our approach was to specifically inhibit Src expression in 
the tumor tissue. Our aims were (i) to show that we are able to 
inhibit tumor cell growth with Src small hairpin RNA (shRNA), 
(ii) to demonstrate that the growth inhibition was specifically 
related to the inhibition of Src protein and mRNA and, (iii) to 
translate the in vitro findings to in vivo showing inhibition of 
tumor growth in two independent malignant glioma models. 
Lentivirus-mediated gene delivery was chosen because of 
its long-term expression capability and high tropism for the 
central nervous system.15,16 ShRNAs, the mediators of RNA 
interference,17–19 enabled us to specifically inhibit Src kinase 
in tumor cells.
Gene transfer vectors used in this study were first char-
acterized in vitro for their efficacy. In vivo experiments were 
started in subcutaneous glioma model for preliminary screen-
ing of treatment responses. Results were further confirmed 
in a syngenic orthotopic rat glioma model closely resembling 
human malignant glioma. Src shRNA approach was also com-
bined with standard chemotherapy and histone deacetylase 
inhibition to enhance the treatment response. As a result, we 
describe an efficient inhibition of Src expression in vitro and 
in vivo, which led to impaired tumor cell growth in two different 
glioma models. We conclude that Src is a potential target for 
RNA interference-based gene therapy for malignant glioma.
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Malignant glioma is a severe cancer with a poor prognosis. Local occurrence and rare metastases of malignant glioma make it a 
suitable target for gene therapy. Several studies have demonstrated the importance of Src kinase in different cancers. However, 
these studies have focused mainly on Src-deficient mice or pharmacological inhibitors of Src. In this study we have used Src 
small hairpin RNAs (shRNAs) in a lentiviral backbone to mimic a long-term stable treatment and determined the role of Src 
in tumor tissues. Efficacy of Src shRNAs was confirmed in vitro demonstrating up to 90% target gene inhibition. In a mouse 
malignant glioma model, Src shRNA tumors were almost 50-fold smaller in comparison to control tumors and had significantly 
reduced vascularity. In a syngenic rat intracranial glioma model, Src shRNA-transduced tumors were smaller and these rats had 
a survival benefit over the control rats. In vivo treatment was enhanced by chemotherapy and histone deacetylase inhibition. 
Our results emphasise the importance of Src in tumorigenesis and demonstrate that it can be efficiently inhibited in vitro and 
in vivo in two independent malignant glioma models. In conclusion, Src is a potential target for RNA interference-mediated 
treatment of malignant glioma.
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Results
In vitro functionality
To establish efficient tools for further experiments, the func-
tionality of Src shRNA constructs were analyzed on mRNA 
as  well  as  on  protein  level  for  target  gene  knockdown 
 ( Figure 1a,b). Both selected shRNAs were able to reduce 
Src gene expression up to 90% in comparison to nontrans-
duced  (NT)  and  control-transduced  (Ctrl)  cells.  In  addi-
tion, Src downstream target and tumor microenvironment 
molecule matrix metalloproteinase 2 (MMP-2) was down-
regulated in cell culture supernatants after Src inhibition 
(Figure 1a). To assay the biological functionality of shRNA 
constructs, cell viability was measured by MTT assay and 
angiogenesis mimicked in vitro by tubulogenesis on Matri-
gel. The  viability  of  NT  and  Ctrl  cells  enhanced  signifi-
cantly after vascular endothelial growth factor-stimulation, 
whereas Src-inhibited cells gained only little viability benefit 
(Figure 1c). Furthermore, the overall levels of cell viabil-
ity  in  Src  shRNA-treated  groups  were  remarkably  lower 
compared to the controls. Control cells cultured on Matrigel 
started to form tube-like structures within a few hours after 
the cells were plated. Tubules were most prominent 6 hours 
post-plating (Figure 1d, top panel) and started to slowly 
disintegrate thereafter. Tubulogenesis in Src-inhibited cells 
was clearly disturbed as demonstrated by cells remaining 
apart from each other throughout the observation time and 
failing to make tube-like structures. Fluorescence micros-
copy was used to confirm the expression of shRNAs during 
the experiment (Figure 1d, bottom panel).
Tumor  growth  and  marker  gene  expression  in  mouse 
xenograft
To study the efficacy of Src shRNA in vivo, we established a 
xenograft from the U118MG cell line. Tumor growth was mea-
sured weekly over 6 weeks of follow-up. After 3 weeks, growth 
differences between groups 5 and 8 (Table 1) in comparison 
to other groups started to emerge (Figure 2a). This difference 
increased toward the end of the experiment. At the end of the 
Figure 1  Functionality of small hairpin RNAs (shRNAs) in vitro. (a) Inhibitory effects of shRNAs against Src kinase were analysed in 
  human umbilical vein endothelial cells (HUVECs) on a protein level by western blotting. β-Actin was used as a normalization control for sample loading. 
Effect of Src inhibition on the cell secretion of matrix metalloproteinase 2 (MMP-2) was analyzed from +/− EGF-stimulated U118MG cell supernatants. 
Quantifications of western blots are shown below each lane. (b) Src inhibition in HUVECs was also measured on mRNA level by quantitative real-time 
reverse transcription (RT)-PCR. Target gene expression was normalized to GAPDH mRNA expression. **P < 0.01 versus nontransduced cells. (c) The 
effect of   vascular endothelial growth factor (VEGF)-stimulation (50 ng/ml) on cell viability was measured by MTT assay in cells transduced with shRNAs. 
*P < 0.05; ***P < 0.001 versus nonstimulated cells. (d) To mimic angiogenesis in vitro, transduced cells were plated on growth factor reduced Matrigel 
and monitored over a period of several hours. Light and fluorescence microscopic pictures were taken. Representative pictures are from 6 hours time-
point. 40× magnification, scale = 1 mm. +, stimulated; −, nonstimulated; Ctrl, transduced with a control vector expressing shRNA against   luciferase; EGF, 
epidermal growth factor; NT, nontransduced; sh1, shRNA sequence 1 against Src; sh2, shRNA sequence 2 against Src. Error bars = SEM.
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study (6 weeks postimplantation) the smallest tumors were 
<20 mm3 in size in comparison to the control tumors, which 
were almost 50-fold bigger. The tumors having Src shRNAs 
expressed in close to 100% of the cells were unable to grow. 
The groups having 10% and 50% cells transduced with Src 
shRNAs did not show reduced growth in comparison to NT 
tumors. The mean tumor volume and corresponding standard 
error of mean for each group at 6 weeks timepoint was: NT 
1,068 (±168), Ctrl 100% 654 (±141), sh1 10% 1,141 (±199), 
sh1 50% 934 (±146), sh1 100% 13.7 (±4.2), sh2 10% 1,313 
(±251), sh2 50% 1,018 (±172), sh2 100% 13.8 (±3.7). Trans-
duction efficiency was confirmed by green fluorescent protein 
(GFP) marker gene expression both preimplantation (data 
not shown) and postsacrifice (Figure 2b). Tumor morphology 
assessed by hematoxylin–eosin staining showed no marked 
differences between the treatment groups (data not shown).
Src expression and interferon response
Src  expression  was  studied  from  tumors  by  western  blot-
ting and immunohistochemistry. Tumors in groups 5 and 8 
had reduced Src expression in western blot shown on lanes 
labelled sh1 and sh2 (Figure 3a) as well as in immunohis-
tochemistry (Figure 3b) in comparison to NT tumors and in 
tumors transduced with a control vector. Tumor lysates were 
analyzed for MxA, a central interferon-responsive gene,20 in 
order to exclude this interferon response pathway as a pos-
sible mediator of the differences in tumor sizes. None of the 
tumor lysates expressed MxA when compared to the extracts 
from positive control cells (Figure 3a).
Tumor vascularity and proliferation
Tumor capillaries were visualized using an anti-CD34 stain-
ing for endothelial cells. Microvessel density, namely the num-
ber of capillaries/mm2, was significantly reduced in both Src 
shRNA groups 5 and 8 (Figure 4). Capillaries in Src-inhibited 
tumors appeared smaller in size and stained less intensively 
compared to NT and control vector-transduced tumors. Tumor 
sections were also stained for anti-α-smooth muscle actin for 
the detection of pericytes to distinguish whether the compo-
sition of vessel wall was different after the treatments. Only 
a few pericyte-covered vessels were detected at the tumor 
borders and there were very few positive vessels in any of the 
study groups (data not shown). Tumors were also analyzed 
for lymphatic vessels, which showed no consistent differences 
after Src inhibition (data not shown). No significant differences 
were found in tumor proliferation indexes between the different 
treatment groups (Figure 5) although the group 8 with all cells 
transduced with Src shRNA2 showed a decreased trend.
Rat malignant glioma model
Both in vivo and ex vivo gene transduction approaches were 
studied in an intracranial rat glioma model. Ex vivo admin-
istrated Src shRNA1 gave rats a significant (***P < 0.001)   
survival  benefit  in  comparison  to  rats  having  NT  tumors   
(Figure  6a).  Median  survival  for  Src  shRNA1  rats  was 
68 days and for rats with NT tumors 37 days. Overall, rats 
treated with ex vivo gene transductions had increased sur-
vival compared to in vivo-treated rats. Tumor volumes were 
measured every week by MRI. Src inhibited tumors (Src sh1_
ex vivo) were significantly smaller than NT or control virus 
transduced (Ctrl_ex vivo) tumors at corresponding timepoints   
(Figure 6b). For example at day 35 mean tumor volumes 
were 20 mm3 (Src sh1), 123 mm3 (Ctrl), and 305 mm3 (NT). 
At that timepoint Src sh1 transduced tumors were 6.6% of the 
corresponding NT tumors. Gene transfer efficacy was also 
studied in order to elucidate survival differences between in 
vivo and ex vivo approaches (Supplementary Materials and 
Methods). In vivo gene transfer efficacy was 6.0% 5 days 
after gene transfers (day 19 postimplantation). Correspond-
ing ex vivo transduction efficacy was 9.7% 20 days after the 
tumor cell implantation (Supplementary Figure S1).
Src shRNA treatment was also combined with sodium val-
proate  (VPA)  and/or  temozolomide  (TMZ)  treatments.  We 
have previously shown that VPA enhances gene expression 
intensity followed by lentiviral transduction (data not shown). 
Combinations of Src shRNA with VPA and/or TMZ were first 
tested in vitro by MTS viability assay (Supplementary Materi-
als and Methods). Full combination of Src sh1, VPA, and TMZ 
decreased cell survival the most compared to single or dual 
treatments (Supplementary Figure S2). Full combination of all 
three treatments resulted in cell viability of 8.1% of Src shRNA 
alone treatment. In vivo full combination of Src sh1, VPA, and 
Table 1  Study groups
Group Species Treatment Treatment administration N (tumors)
I Mouse Nontransduced (NT) Ex vivo, s.c. 10
II Mouse Control virus (Ctrl) ~100% Ex vivo, s.c. 8
III Mouse Src shRNA1 ~10% Ex vivo, s.c. 9
IV Mouse Src shRNA1 ~50% Ex vivo, s.c. 9
V Mouse Src shRNA1 ~100% Ex vivo, s.c. 10
VI Mouse Src shRNA2 ~10% Ex vivo, s.c. 9
VII Mouse Src shRNA2 ~50% Ex vivo, s.c. 9
VIII Mouse Src shRNA2 ~100% Ex vivo, s.c. 10
IX Rat Nontransduced (NT) In vivo, i.c. 12
X Rat Control virus (Ctrl) In vivo, i.c. 4
XI Rat Src shRNA1 In vivo, i.c. 9
XII Rat Control virus (Ctrl) ~100% Ex vivo, i.c. 8
XIII Rat Src shRNA1 ~100% Ex vivo, i.c. 9
XIV Rat Src shRNA1 + VPA In vivo, i.c. 5
XV Rat Src shRNA1 + TMZ In vivo, i.c. 4
XVI Rat Src shRNA1 + VPA + TMZ In vivo, i.c. 5
Abbreviations: %, approximate percentage of transduced cells; Ctrl, expresses shRNA against luciferase; i.c., intracranial tumor; s.c., subcutaneous tumor; 
TMZ, Temozolomide; VPA, sodium valproate.Molecular Therapy–Nucleic Acids
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TMZ had a clearly reduced tumor volume being 59% of Src sh1 
alone (Figure 6c). TMZ added to Src sh1 was able to decrease 
mean tumor volume to 76% of Src sh1 alone. Addition of VPA to 
Src sh1 did not differ from Src sh1 alone. Representative day 35 
MRI data is shown for some of the treatment groups (Figure 6c).   
Survival of rats was also studied after combination treatment. 
There was no survival benefit with combination treatment in 
comparison to single or dual treatments (Figure 6d).
Discussion
Src was the first kinase to be characterized in late 1970s21 and 
the knowledge about it has vastly expanded since then.11,22 It 
is crucial for various cellular responses downstream of sev-
eral important growth factor receptors.9,10 These properties 
make its inhibition a potential cancer therapy approach. On 
the other hand, these same properties make it a less desir-
able target elsewhere in the body when considering poten-
tial adverse effects of systemically administrated treatments. 
Importantly, a need for high systemic concentrations in order 
to reach effective treatment levels in a target tissue is likely to 
cause unwanted side effects.23 By using local gene therapy 
one could circumvent some systemic adverse effects.
To address these issues we studied lentiviral RNA inter-
ference-mediated  inhibition  of  Src  in  order  to  restrict  the 
growth of malignant glioma. For preliminary in vitro screen-
ing, human umbilical vein endothelial cells (HUVECs) were 
used  to  evaluate  the  functionality  of  the  lentiviral  RNA 
  interference-mediated  Src  inhibition  since  Src  has  been 
shown  to  be  biologically  important  and  highly  expressed 
in endothelial cells.10,24 Being primary cells, HUVECs also 
resemble  in  vivo  conditions  better  than  immortalized  cell 
lines. ShRNAs targeting Src were shown to be functional 
and highly efficient when measured by mRNA and protein 
levels.  According  to  requirements  for  RNA  interference-
based  studies,25  shRNAs  were  further  tested  in  suitable 
functionality assays, namely cell viability and tubulogenesis 
assays. Sequences were searched for homology to unrelated 
targets  and  an  irrelevant  vector-matched  control  shRNA 
against luciferase was used in every experiment. Upstream 
from Src are several growth factors out of which vascular 
endothelial growth factor mediated cell viability was shown 
to decrease after Src inhibition. Reduced MMP-2 levels con-
firmed  impaired  downstream  signalling  mediated  through 
Src kinase.9 MMP-2 has also shown to be a crucial factor for 
tumor invasiveness and metastasis further emphasising the 
importance of its inhibition.2
Figure 2  Mouse tumor growth kinetics and marker gene expression.  (a) Tumor growth kinetics were measured over 6 weeks 
follow-up. U118MG glioma cells were transduced with lentiviral vectors encoding small hairpin RNAs (shRNAs) against Src kinase and 
luciferase as a control. Different proportions of transduced cells were implanted subcutaneously on flanks of nude mice and tumor growth 
was measured weekly in different treatment groups. The insert shows tumor growth of sh1 100% and sh2 100% groups over the same 
study period with a more detailed scale of y axis. P < 0.05 Ctrl versus sh1/sh2 100%. (b) Maintenance of stable transduction throughout 
the experiment was confirmed by green fluorescent protein (GFP) marker gene expression in frozen tumor sections. Representative 
sections are from a tumor formed by control virus transduced cells. 100× magnification, scale = 200 µm. Ctrl, transduced with a control 
vector expressing shRNA against luciferase; NT, nontransduced; sh1, shRNA sequence 1 against Src; sh2, shRNA sequence 2 against 
Src; shRNA, small hairpin RNA.
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In a nude mouse glioma model, both Src shRNAs were 
able to almost completely abolish the tumor growth when 
expressed by all tumor cells. Cells were not sorted by fluores-
cence-activated cell sorting, which resulted in the presence 
of some nontransduced cells. In practice, the proportions of 
transduced tumor cells were >97% in these groups measured 
by   fluorescence-activated cell sorting. In mice having only 
50% or 10% of tumor cells transduced, tumor growth was 
comparable to NT tumors. Based on these results, it could 
be estimated that the threshold portion of the transduced 
cells  needed  to  retain  the  growth  block  was  somewhere 
between  50%  and  100%  taking  into  account  the  timeline 
of  the  experiment.  Slower  growth  and  smaller  volumes  of 
the  control  vector-transduced  tumors  were  likely  caused 
by having all tumor cells transduced by the vector occupy-
ing cellular machinery and slowing down the growth. MxA, 
a central interferon-responsive protein, was analyzed from 
the mouse tumor lysates in order to exclude its influence in 
this approach. It is well known that double-stranded RNA and 
RNA interference can trigger interferon response and thus 
cause inefficient response to shRNA therapy.20,26 Since MxA 
was only expressed in positive control cell lysates, it can be 
concluded that neither shRNAs themselves nor lentiviral vec-
tors induced the interferon response pathway, which could 
explain the differences in tumor growth. However, it is pos-
sible that some other signalling pathways not examined here 
could  have  contributed  to  the  reduced  growth  rate.  Other 
explanations for the off-target effect in shRNA approaches 
could be related to unintentional miRNA inhibition caused by 
shRNA overexpression and perturbation of gene regulation 
through miRNAs.27,28 If this is the case, the shRNA therapy 
that we are proposing could be improved by regulating the 
intracellular shRNA levels for example with regulated or tis-
sue specific expression systems.27,29
Src protein expression was analyzed from mouse tumor 
lysates by western blot and shown to be reduced in Src-inhib-
ited tumors. This was verified with immunohistochemistry by 
staining corresponding tumor sections with anti-Src antibody. 
Intensity of the staining was clearly reduced in Src-inhibited 
tumors. In Src-inhibited tumors there were significantly less 
vessels and they were smaller in size compared to NT and con-
trol vector-transduced tumors. These vessels were confirmed 
Figure 3  Expression of Src and interferon-responsive MxA 
in mouse tumors. (a) Western blot was used to analyze Src and 
MxA protein expression from tumor lysates. β-Actin was used as a 
loading control. Normalization of Src by actin is shown below each 
lane of the corresponding blot. Lanes: NT1-2 =   nontransduced 
tumors, C6−C7 = control virus transduced tumors, sh1 = tumor 
transduced with shRNA1 against Src, sh2 = tumor transduced 
with shRNA2 against Src, +24 and +48 = interferon-induced cell 
lysates collected at 24 and 48 hours postinduction (positive con-
trols). (b) Immunostaining against Src, 200× magnification, scale = 
100 µm. Ctrl, transduced with a control vector expressing shRNA 
against luciferase; NT, nontransduced; sh1, shRNA   sequence 1 
against Src; sh2, shRNA sequence 2 against Src; shRNA, small 
hairpin RNA.
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to be small capillaries based on nonexistent pericyte coverage 
after α-smooth muscle actin staining. Lymphatic vessels were 
scarce and showed no differences between different treat-
ments. The smaller size and reduced capillary number of Src 
inhibited tumors is in agreement with the general notion that 
a tumor cannot grow bigger than ~1 mm in diameter without 
new capillaries to support its nutrient and oxygen demands.30 
Tumor proliferation did not significantly vary between differ-
ent  treatments,  although  Src  sh2_100%  group  showed  a 
decreased trend. In support of this, current data from many 
tumor cell types and clinical trials of Src inhibitors have not 
shown objective responses on proliferation.31,32
The maintenance of high transduction efficacies throughout 
the nude mouse glioma experiment was confirmed postsacri-
fice by GFP fluorescence microscopy. This confirmed the sta-
ble long-term transgene expression characteristic of lentiviral 
vectors.33 In addition, lentiviral vectors have shown to have high 
tropism for neural tissues.15,16 They can be targeted or delivered 
locally  into  tumor  mass  therefore  reducing  off-target  effects 
and systemic toxicity. One of the pitfalls of in vivo gene ther-
apy has been relatively low transduction efficacy. This aspect 
needs further optimization and several strategies are currently 
under investigation.6,34 With lentiviral vectors, viral purification 
has been shown to increase transduction efficacy35,36 and is 
expected to cause less immune response and may therefore 
enable consecutive viral administrations, if necessary.
The  growth  deterioration  following  Src  inhibition  was  fur-
ther confirmed in an orthotopic rat glioma model, which has 
been shown to closely resemble human malignant glioma.34,37 
Rats treated with ex vivo Src inhibition had significant survival 
benefit and decreased tumor volumes in comparison to rats 
having NT tumors. Similar benefit was not seen with in vivo 
gene transfer. In vivo gene transfer efficacy was 6.0%, which 
supports the observation from our mouse glioma model that 
over 50% transduction efficiency is needed in order to see Src-
mediated inhibition of tumor growth. Ex vivo gene transfer effi-
cacy was ~94% preimplantation. However, only 9.7% of cells 
were GFP-positive 20 days postimplantation. This difference is 
likely explained by overgrowth of nontransduced cell popula-
tion and possibly immune response against nonmammalian 
GFP protein included in the viral construct.38 Similar reduction 
of gene transfer efficacy was not seen in nude mouse glioma 
model possibly due to the compromised immune response in 
these mice. To reach high gene transfer efficiency and improved 
treatment response, one needs to either transduce ex vivo and 
sort the cells to be 100% transgene positive, use replication 
competent vectors or systems with a bystander effect.6,39
Another way to enhance the efficacy is to combine gene 
therapy with standard treatments. In this study, we combined 
Src inhibition with TMZ and/or VPA. Rational for this was that 
TMZ is being currently used for standard therapy of glioblas-
toma multiforme and VPA (being a histone deacetylace inhib-
itor) has shown its potential in enhancing gene expression.40 
When combined all together, we were able to clearly reduce 
the tumor volume to 59% of Src sh1 alone. However, this did 
not result in corresponding benefit in rat survival. It is known 
that antiangiogenic compounds can interact with other can-
cer drugs in several ways making it critical to evaluate dosing 
and scheduling in detail. Some studies have shown that pre-
treating with an antiangiogenic compound will normalize the 
vasculature and thus the chemotherapeutic agent uptake into 
tumor will be enhanced.41 This increase in vascular patency 
is transient and thus the “window of opportunity” needs to be 
carefully determined.
As  generally  acknowledged,  no  single  gene  therapy  is 
likely to be sufficient for a complex disease like cancer.4 As 
a combination therapy, Src inhibition could be a useful tool, 
not only by directly restricting the tumor growth, but also by 
normalizating the tumour vasculature and controlling tumor 
invasiveness and thereby metastasis in tumor types prone 
to metastasise.31,42 As the treatment regimens are moving 
toward combination therapies, Src inhibition could be ben-
eficial in several combinations. However, to improve thera-
peutic responses, combination of several treatments requires 
careful optimization of dosing, scheduling and interactions 
between the individual treatments.43
Materials and methods
shRNAs  and  lentiviral  vectors.  Lentiviral  vectors  contain-
ing  shRNA  inserts  against  Src  kinase  (LV.shSRC1  and 
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Figure  5  Tumor  proliferation.  (a)  Ki-67  immunostaining  for 
  tumor proliferation and (b) proliferation indexes in mouse tumors, 
200× magnification, scale = 100 µm. Indexes as percentage (%) of 
proliferating cells from all the cells in different treatment groups are 
shown. Ctrl, transduced with a control vector expressing   shRNA 
against luciferase; NT, nontransduced; sh1, shRNA sequence 1 
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LV.shSRC2)  and  luciferase  (LV.shGL3)  as  a  control  were 
selected  from  shRNA  lentivirus  library  provided  by  the 
Genomics  Institute  of  Novartis  Research  Foundation  (San 
Diego). All vector constructs included a sense-loop-antisense 
hairpin structure driven by H1 promoter and a GFP marker 
gene driven by CMV promoter. Target sequences of shRNAs 
were: 5′-gctgttcggaggcttcaac-3′ (shSRC1), 5′-gggcctcaacgt-
gaagcac-3′ (shSRC2) and 5′-gacgaacacttcttcatcg-3′ (shGL3). 
Third generation, self-inactivating lentiviruses were prepared 
by standard calcium phosphate transfection method in 293T 
cells as described.44 Viral preps were titered in HeLa cells with 
biological titers ranging form 2.0 × 108 to 3.7 × 108 TU/ml.
Cell culture and viral transduction. Original screening of Src 
shRNAs for target inhibition efficiency was conducted in low 
passage  HUVECs.  HUVECs  were  isolated  from  umbilical 
cords obtained from the maternity unit of the Kuopio Uni-
versity  Hospital,  by  the  approval  of  the  Kuopio  University 
Hospital Ethics Committee. HUVECs were cultured on plas-
tic ware coated with 0.05% gelatin/10 µg/ml fibronectin and 
maintained in endothelial basal medium with growth supple-
ments (Lonza, Cologne, Germany). For glioma experiments 
U118MG cells (ATCC: HTB-15) were used in vitro as well 
as for mouse ex vivo implantations. BT4C cells45 were used 
in rat malignant glioma model. Glioma cells were grown in 
Dulbecco’s  modified  Eagle’s  medium  supplemented  with 
10% fetal bovine serum and 1% penicillin–streptomycin. For 
MMP-2 analysis U118MG cells were serum starved (0.5% 
fetal bovine serum) and stimulated with 100 ng/ml epidermal 
growth  factor  (R&D  Systems,  Minneapolis,  MN).  Lentiviral 
transductions were done with MOI 5 for HUVECs, MOI 10 
for U118MG cells and MOI 20 for BT4C cells. Basal growth 
medium was changed for the cells the following day. In each 
experiment transduction efficiency was monitored by fluores-
cence microscopy (Olympus IX71, Olympus, Tokyo, Japan) 
and fluorescence-activated cell sorter (FACScalibur; BD Bio-
sciences, Franklin Lakes, NJ) measuring GFP.
Real-time  reverse  transcription-PCR.  Total  RNA  was 
extracted  from  cells  by Tri  Reagent  (Invitrogen,  Carlsbad, 
CA) according to manufacturer’s protocol. RNA was reverse 
transcribed to cDNA by M-MuLV reverse transcriptase (Fer-
mentas, Leon-Rot, Germany). Target gene mRNA levels were 
measured  by  real-time  PCR  (ABI  PRISM  7700  detection 
system;  Applied  Biosystems)  using  specific Taqman  gene 
expression assays (Applied Biosystems, Foster City, CA) for 
human Src (Hs00178494_m1) and GAPDH (4333764F) for 
normalization.
Western blot. Cultured cells were lysed and protein concentra-
tions measured by BCA assay (Thermo Scientific, Rockford, 
IL). 20–30 µg of total proteins were run on polyacrylamide 
gel electrophoresis and transferred on nitrocellulose mem-
brane. Blocked blots were incubated with a primary antibody 
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(Src: Cell Signalling Technology, Danvers, MA; MMP-2: R&D 
Systems Inc.; MxA: a kind gift from professor Ilkka Julkunen, 
The National Institute for Health and Welfare, Helsinki, Fin-
land; β-actin: Abcam, Cambridge, UK) followed by a corre-
sponding secondary antibody (goat anti-rabbit IgG-HRP, goat 
anti-mouse IgG-HRP: Thermo Fisher Scientific, Rockford, IL). 
Blots were visualized using ECL Plus western Blotting Detec-
tion System with Typhoon 9400 (GE Healthcare, Piscataway, 
NJ).
Cell viability assay. HUVECs were transduced with lentivi-
ral vectors and 4 days post-transduction 5,000 cells were 
replated  on  96-well  plates.  Cells  were  let  to  adhere  and 
serum-deprived medium containing 0.5% fetal bovine serum 
was changed to the wells the following day. After 24 hours, 
stimulation medium containing 50 ng/ml recombinant human 
vascular  endothelial  growth  factor  in  serum-deprivation 
medium  was  added  on  cells.  MTT  (3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyl tetrasodium bromide) assay, CellTiter-Glo 
Luminescent  Cell Viability  Assay  (Promega,  Madison, WI) 
was performed at 48 and 72 hours poststimulation according 
to the manufacturer’s protocol.
In vitro angiogenesis. HUVECs were transduced with lentivi-
ral constructs and 4 days post-transduction 40,000 cells were 
replated on 48-well plates coated with growth factor reduced 
Matrigel (BD Biosciences) diluted 1:1 with basal medium, all 
together 150 µl/well. Cells were monitored and pictures were 
taken during the next 24 hours with light as wells as fluores-
cence microscopy. Representative pictures are from 6 hours 
timepoint.
Mouse malignant glioma model. U118MG human malignant 
glioma  cells  were  transduced  with  lentiviral  shRNA  con-
structs  against  Src  and  luciferase  4  days  preimplantation. 
Transduction efficiencies were confirmed, cells were counted 
for viability and suspended in Optimem medium (Invitrogen). 
Cell  suspensions  were  prepared  to  implant  250,000  cells 
in 50 µl volume/tumor, 2 tumors/mouse in NMRI nude mice 
(Taconic, Ejby, Denmark). There were five mice/group result-
ing in ~10 tumors/group. The treated mice were divided into 
eight groups as described in Table 1. In groups 3, 4, 6, and 
7 cell suspensions were prepared by mixing transduced cells 
with nontransduced cells. Cells were injected in both flanks 
of sedatated mice with a 27 G needle. During the experiment 
tumors were weekly measured in three dimensions and vol-
umes calculated using the formula 4/3πr3. All mice were sac-
rificed at 6 weeks timepoint.
Rat malignant glioma model. Rat malignant glioma cells were 
inoculated intracranially as described previously34 in inbred 
male BDIX rats (Charles River Laboratories, Lille, France). 
Briefly, 10,000 BT4C cells in 5 µl Optimem medium were 
inoculated  over  right  corpus  callosum  under  stereotactic 
guidance. Coordinates were 1 mm caudal to bregma, 2 mm 
right of sagittal suture, and a depth of 2.5–3.0 mm. Inocu-
lations were done slowly over 5 minutes to avoid backflow 
and needle was left in place for another 5 minutes. In ex vivo 
transduced tumors cells were transduced 4 days preinocula-
tion as described above. shRNA1 against Src was used in 
this model due to its sequence homology to rat Src mRNA. All 
rats were imaged with MRI at day 12 postinoculation to con-
firm tumor existence and in vivo gene transfers were done at 
days 13 and 14 as described by Tyynelä et al.37 A total volume 
of 20 µl of virus (LV.shSRC1 or LV.shGL3) was administrated 
stereotactically  at  multiple  sites  to  cover  the  tumor  area. 
Thereafter rats were imaged once a week for tumor growth 
follow-up. For rats receiving VPA subcutaneous injections of 
200 mg/kg Deprakine (Sanofi Winthrop Industrie, Ambarès, 
France) were given twice a day for 14 days starting at day 19 
postinoculation. VPA was also administered once preceed-
ing gene transfers at days 13 and 14. For rats receiving TMZ 
i.p. injections of 20 mg/kg Temodal (SP Europe, Bruxelles, 
Belgium) were given once a day for 5 days starting at day 
28 postinoculation. Temodal capsules were dissolved 1:9 in 
DMSO:0.9% saline to yield final concentration of 20 mg/ml. 
All animal procedures were approved by the Experimental 
Animal Committee of the University of Kuopio.
MRI.  Magnetic  resonance  imaging  (MRI)  was  used  in  rat 
malignant glioma model for confirmation of tumor existence 
(day 12 postinoculation) and weekly tumor growth follow-up 
after the gene transfers. For rats undergoing MRI, anesthesia 
was induced with 5% isoflurane gas, in a gas chamber having 
a 70:30% mixture of N2O:O2 and anesthesia was maintained 
at 1.5% isoflurane. MRI scans were acquired on a 4.7 T small 
animal MRI scanner (Magnex Scientific, Abington, UK) inter-
faced to a Varian Unity Inova (Palo Alto, CA) console or a 9.4 
T small animal MRI scanner (Varian Medical Systems, Palo 
Alto, CA) interfaced to a Varian DirectDrive console. Noncon-
trast enhanced, T2-weighted fast spin-echo images of 17 cor-
onal images (1 mm thickness, no gap between slices) were 
positioned to cover the tumor area in the rat brain. The details 
for the MRI contrast parameters for the 4.7 T MRI scanner 
were as follows: spin-echo preparation with 80 ms echo time 
and repetition time 2.5 seconds. The field of view of 40 × 40 
mm with 256 × 256 data matrices resulted in pixel size of 
(0.16 mm)2. For the 9.4 T MRI scanner parameters were as 
follows: spin echo preparation with 40 ms echo time, followed 
a segmented fast spin echo with four echoes per excitation 
and echo time of 8 ms, repetition time of 3 seconds. Field of 
view of 30 × 30 mm with 256 × 128 data matrices (zerofilled 
to 256 × 256) resulted in pixel size of (0.12 mm)2. The total 
tumor volumes were calculated by delineating the tumor area 
in all the image slices using a home-built Matlab program 
Aedes (http://aedes.uku.fi; MathWorks, Natick, MA).
Immunohistochemistry. Isopentane-frozen tumor sections (10 
µm) were used to check the maintenance of tumor transduc-
tion by GFP. PFA-fixed paraffin-embedded tumor sections (4 
µm) were used for all other immunohistochemical stainings. 
General morphology of tumors was analyzed from hematoxy-
lin–eosin stainings. Tumor sections were also immunostained 
for Src (1:50; Cell Signalling Technology), mouse CD34 (1:10; 
HyCult Biotechnology b.v., Uden, the Netherlands), LYVE-1 
(1:1,000; ReliaTech, Braunschweig, Germany), Ki-67 (1:50; 
Dako, Glostrup, Denmark) and anti-Muscle Actin (HHF35) 
(1:50; Enzo Life Sciences, Farmingdale, NY). Control immu-
nostainings  were  conducted  without  the  primary  antibody. 
Histological sections were assessed using Olympus AX-70 www.moleculartherapy.org/mtna
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microscope (Olympus) with analySIS software (Soft Imaging 
System, Münster, Germany). Ki-67 quantifications were done 
by an experienced pathologist in a blinded-manner. For tumor 
capillaries, CD34 stained microscopic slides were evaluated 
and vascular “hot-spots” from five microscopic fields46 were 
counted.
Statistical  analysis.  All  experiments  were  carried  out  with 
three or more replicates. Results are expressed as mean ± 
SEM.  Statistical  analyses  were  performed  with  GraphPad 
Prism  version  4.03  (GraphPad  Software,  San  Diego,  CA). 
Kolmogorov–Smirnov  normality  test  was  used  to  assess 
sample  normality.  Kruskall–Wallis  test,  followed  by  Dunn’s 
multiple comparison test, was used as a nonparametric test 
and unpaired t-test as a parametric test when relevant. P < 
0.05 was considered statistically significant.
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